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Introduction
Glioblastoma multiforme (GBM), a highly aggres sive brain cancer characterized by uncontrolled pro liferation, resistance to cell death, angiogenesis, and vascular edema, remains one of the deadliest types of cancer [2, 17, 21] . The current standard of care involves aggressive surgery, radiation and chemothe rapy, yet provides only a modest survival benefit [16, 27, 37] .
Based on cancer stem cell theory, and images of GBMs, recently there has been advanced a rele vant classification related to the subventricular zone (SVZ) and its survival impact [18, 22, 24] . Since the SVZ harbors cells with great proliferative potential and the microenvironment within the SVZ is permis sive to growth and proliferation, this neurogenic niche is suspected to be a vulnerable site for the origin of subtypes of GBM [13] . Recently, there has been a consensus about the subpopulation of can cer cells with stem cell characteristics, including self renewal and multipotentiality; these cancer stem cells can propagate tumors in vivo [8, 12] . Recent evi dence suggests that tumor location plays an import ant role in prognosis and is likely related to the genetic profile of tumor cells of origin [18, 30] . Fur thermore, some authors have constructed prognos tic models and analyzed probabilistic radiographic atlases of GBM phenotypes [11, 13] .
The GBM heterogeneity has motivated several studies to evaluate factors that predict prolonged survival for patients with GBM [4, 18, 20, 24, 38] . Such heterogeneity could be related, according to some authors, to the stem celllike characteristics [24] . Lim et al. proposed a classification scheme that divides the GBMs into four groups by the spatial relationship of the contrastenhancing lesion with the subventricular zone and cortex: type I -tumor in which the contrastenhancing lesion contacts both the SVZ and the cortex; type II -tumor con tacts the SVZ but not the cortex; type III -tumor contacts the cortex but not the SVZ; and type IV -tumor contacts neither the SVZ nor the cortex. Regarding the multifocal and/or multicentric GBMs there are many theories showing a close associa tion with group I given the findings consistent with high migratory and invasiveness of cells, according to Willis' theory [24, 33] .
Based on recent studies [39] , YKL40, also known as chitinaselike protein 1, is included as a mesen chymal marker and associated with a poor progno sis. The protein is a secreted inflammatory molecule with no chitinolytic activity [15] YKL40 has been pos tulated as a potential serum marker in glioblastoma [4, 19] since it was found to have elevated levels in the serum of patients with GBM. However, the muta tion of IDH1 (mIDH1) has been found in the cyto plasm and peroxisomes of 7080% of secondary GBMs. mIDH1 is a selective marker for secondary glioblastoma supplementing clinical judgment to dis tinguish it from primary glioblastoma. There are few reports related to the mutated IDH1 expression and its subventricular zone relationship [11] . The aim of our study was to determine the immunohistochemi cal expression of mIDH1 and YKL40 in relationship to the SVZ of GBMs.
Material and methods
A retrospective study was performed on 204 GBMs operated on at the Neurosurgical Unit of Asturias Hospital, Spain, between December 2005 and September 2011. We divided the GBMs into five groups. The first four groups were selected accord ingly to the Lim [24] classification. We then selected multifocal or multicentric presentation of GBMs as a fifth group.
Detailed data regarding clinical presentation, imaging features, surgical procedure, pathological analysis, oncological treatment, progressionfree survival (PFS), and overall survival (OS) outcome were recorded. The extent of resection was deter mined by early postoperative MRI (within 48 hours). Subtotal and total resection were defined as those tumors with residual and no residual enhancement, respectively, achieved by comparing pre and post operative MRI. Extent of resection was classified as either total (> 95%), subtotal (< 95%) or biopsy by a neuroradiologist blinded to patient outcomes. Patients were informed of the investigational nature of this study and written informed consent was obtained from each patient in accordance with insti tutional guidelines. Patients with a Karnofsky Per formance Scale (KPS) score ≥ 70 and age < 60 were included to receive conventional radiotherapy and chemotherapy after surgical resection: 1.82.0 Gy per day, over a period of 6 weeks, for a total dose of 60 Gy and temozolomide therapy at a dose of 75 mg/m 2 per day, seven days a week for 42 con secutive days during radiotherapy (as used in the EORTC study by Stupp et al.) [3, 23, 36] .
The pathology was determined by a senior neu ropathologist in all instances, and the grading cri teria were based on the World Health Organization (WHO) classification system.
All statistical analyses were performed with SPSS Statistics version 20 (IBM) with a significance level of p = 0.05. Fisher's exact test was used for evaluation of the association between YKL40 and mIDH1 (with positive and negative expression) and covariates. Survival analysis was carried out with the KaplanMeier method and a log rank test. For multi variate analysis of OS and PFS, a Cox proportional hazards model was performed using age (< 65 vs. ≥ 65), gender, initial KPS score (< 70 vs. ≥ 70), hemi sphere, subventricular relationship, extent of resec tion, and first line therapy as covariates. All tests were twosided, and a p value of < 0.05 was con sidered significant. The confidence intervals were calculated at the 95% level.
Results
The population of our study consisted of a total of 204 patients harboring GBMs. The baseline clinical data are summarized in Table I . Among the patients in the study, the median age was 63 ± 10.86 years. Most patients were male (115). The median initial KPS score was 80. Overall, for surgical resection, 44 patients underwent gross total resection (GTR), 119 patients underwent subtotal resection (STR), and 41 patients underwent biopsy. Although sta tistically significant (p < 0.05), there was not a greater extent of resection or more radiotherapy combined with chemotherapy, among mIDH1pos itive GBMs.
In 94 patients, YKLpositive cells were identified. YKL40 expression was found predominately in the cytoplasm. YKL40 was strongly stained in all positive samples. One hundred and ten were YKL40 negative. In 42 patients the mIDH1 was positive. One hundred sixtytwo were IDH1 negative.
The (Table II) . The median PFS among those with mIDH1positive GBMs was higher than those with YKL40positive GBMs (1 and 0, respectively).
Tumor location
All tumors were supratentorial in location. We did not find statistically significant differences between the right and left hemisphere linked to YKL40 and mIDH1 immunoexpression. 
Discussion
Patients diagnosed with GBM have a dismal prog nosis [5] . Even though median survival is poor, indi vidual survival is heterogeneous, with some patients surviving for several years [5, 9, 34] . Age at diagnosis, KPS score, and extent of resection have been the most welldocumented predictors of survival. Age has consistently been shown to be one of the most powerful prognostic factors for survival in patients with GBM, with younger patients living much longer than older patients. Furthermore, the poor tolerance of older patients to aggressive toxic systemic che motherapy often results in either treatmentrelated complications and/or suboptimal tumor treatment [10, 28, 31] . In the present study, we found a particu larly strong tendency among young adults to harbor mIDH1positive GBMs. Furthermore, Cox's regres sion model showed that younger patients were associated with better OS, consistent with previ ous published series [2, 6, 7, 26] . Nevertheless, extent of resection remains a topic of debate, particularly for incomplete resections. The most comprehensive work to date on the value of extent of resection sug gests that ≥ 98% is necessary to impact survival in patients with GBM [31, 40] . In our study the extent of resection was not a prognostic factor in the Cox's regression model and in the characteristics linked to YKL40 and mIDH1 expression, judging by postopera tive enhancing MRI rather than by the neurosurgeon himself may be the reason.
In the present study we found that YKL40positive immunoexpression, reflecting the mesenchymal GBM subgroup [9, 15, 39] , was not significant in the OS and PFS Cox's proportional hazards model. Interestingly, our data showed more YKL40positive expression among subventricular contacting GBMs than mIDH1positive GBMs. The expression of mIDH1 is associated with pro longed OS and PFS in a Cox's regression model, con sistent with other populationbased studies of GBMs [14, 29, 32, 35, 41] . The gross total resection and the radiotherapy combin ed with chemotherapy associa tions were not of prognostic value for either OS or PFS.
Recent evidence suggests that GBMs with both SVZ and cortical involvement and SVZ contact alone result in shorter PFS and OS [13, 18] . Interestingly, we found significantly more type III GBMs than the remaining groups among mIDH1positive GBMs. mIDH1 positivi ty was more frequent in secondary GBMs than in pri mary GBMs (37 and 5, respectively). Of note, among YKL40positive GBMs there were more type IV and V than type III GBMs. The main reasons for a less favor able outcome in GBM patients with SVZ involvement
are not yet completely understood. Type IV and V were particularly linked to YKL40positive GBMs. In our series we identified 34 (16.7%) type V GBMs. In the literature, the incidence of multiple lesions at the time of diagnosis ranged anywhere from 0.5 to 20% [14] .
To the best of our knowledge, the immunoexpres sion of YKL40 has never been assessed in the GBMs associated with the subventricular zone. Since 2002 there have been published fewer papers address ing YKL40 and its expression in GBM, even though it seems related to radiotherapy resistance [15] and mesenchymal subtype, and inversely associated with EGFR. Additional studies concluded that patients with tumors adjacent to the SVZ were more likely to be multifocal at diagnosis and to have noncontiguous tumor recurrences [24] . YKL40 positivity contributes to progression of GBM through invasion, anchor ageindependent growth and drug resistance [23] .
Conclusions
According to the findings in the present study and the review of the literature, GBM is a highly aggres sive tumor. Despite modest improvement in the OS of patients with GBM in the last decade, the outcome remains poor. Therefore, the need for more effective novel treatments in this neoplasm is urgently welcomed.
We demonstrate for the first time that YKL40 GBMs are significantly linked to SVZ types IV and V (p < 0.0001). However, it will be necessary to gain more information about its mechanisms of action in order to move forward with the use of YKL40 for potential application in glioma therapy. Our results show the diversity among GBMs related to the SVZ, which should be considered in the design of future targeted therapies. Age less than 65 years, mIDH1 positivity, type III GBMs, and temozolomide therapy are factors that independently predicted a prolonged OS. These results, however, may be limited by an inherent bias in patient selection, which may favor patients with more superficial tumors. We attempted to minimize the limitations by using strict inclusion criteria and Cox's proportional hazard model analysis.
Therefore, despite this potential source of bias, these findings may help to guide treatment paradigms, prognosticate survival, and provide more information for GBM patients through the identification of these prognostic factors.
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